Key Insights

Highlights

Success Rate

81% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

5.6%

3 terminated out of 54 trials

Success Rate

81.3%

-5.3% vs benchmark

Late-Stage Pipeline

17%

9 trials in Phase 3/4

Results Transparency

54%

7 of 13 completed with results

Key Signals

7 with results81% success

Data Visualizations

Phase Distribution

50Total
Not Applicable (16)
Early P 1 (3)
P 1 (7)
P 2 (15)
P 3 (8)
P 4 (1)

Trial Status

Recruiting22
Completed13
Active Not Recruiting10
Withdrawn4
Terminated3
Not Yet Recruiting1

Trial Success Rate

81.3%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (54)

Showing 20 of 20 trials
NCT06733350Phase 4Recruiting

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT03899987Phase 2Active Not Recruiting

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

NCT04513717Phase 3Active Not Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NCT03218826Phase 1Completed

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

NCT06630325Phase 2Terminated

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

NCT04215029Not ApplicableActive Not Recruiting

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans

NCT05487846Not ApplicableRecruiting

Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation

NCT04550494Phase 2Recruiting

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT06325046Not ApplicableRecruiting

Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer

NCT07073794Phase 2Recruiting

Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer

NCT04514484Phase 1Active Not Recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

NCT04037254Phase 1Completed

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NCT06173362Phase 2Recruiting

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

NCT07025369Phase 2Recruiting

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

NCT06650579Phase 3Recruiting

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

NCT04947254Phase 2Recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

NCT03575832Not ApplicableActive Not Recruiting

Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners

NCT04725903Not ApplicableRecruitingPrimary

Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

NCT05320406Phase 2Active Not Recruiting

RElugolix VErsus LeUprolide Cardiac Trial

NCT07276438Not ApplicableRecruiting

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

Scroll to load more

Research Network

Activity Timeline